COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Lennard-Jones Centre > Practical Application of Simulation in the Drug Discovery Industry
Practical Application of Simulation in the Drug Discovery IndustryAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Daniel Cole. Part of the "Advanced Computation for Drug Discovery" event A wide range of simulation and modelling methods are applied to support the drug discovery process. In this presentation we will review a spectrum of methods and consider their relative strengths and weaknesses, in light of the requirements for their practical application in an industrial environment. Ultimately, the value from computational methods is derived by making good decisions regarding the optimisation of compounds, leading quickly to a high quality drug candidate with a good chance of success in clinical trials. We will discuss some of the challenges that this presents, in particular the need to simultaneously balance several, often competing, factors; a process described as multi-parameter optimisation. Finally, we will draw some conclusions regarding the need for new methods and the challenges facing their adoption. This talk is part of the Lennard-Jones Centre series. This talk is included in these lists:Note that ex-directory lists are not shown. |
Other listsCentre for Neuroscience in Education Cancer talks Adrian Seminars in Neuroscience The Archimedeans 2016 School of Clinical Medicine Talks Computer Laboratory Programming Research Group SeminarOther talksIntrinsically Motivating Teachers;STIR's use of Data Driven Insight to Iterate, Pivot and (where necessary) Fail Fast Psychology and Suicidal Behaviour What has Engineering Design to say about Healthcare Improvement? Constraint Analysis and Optimization in Medicine Development and Supply Mysteries of the solar chromosphere explored using the high-resolution observations The MHC ligandome of two contagious cancers within the Tasmanian devil population, Devil Facial Tumour 1 and Devil Facial Tumour 2 |